About Synthetic Biologics (NYSEAMERICAN:SYN)
Synthetic Biologics, Inc. is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The Company is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU).
Industry, Sector and Symbol:
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Sector: Bio Therapeutic Drugs
- Symbol: NYSEAMERICAN:SYN
- CUSIP: N/A
- Web: www.syntheticbiologics.com
- Trailing EPS: ($0.22)
- Return on Equity: -461.33%
- Return on Assets: -103.45%
- Outstanding Shares: 128,570,000
Frequently Asked Questions for Synthetic Biologics (NYSEAMERICAN:SYN)
What is Synthetic Biologics' stock symbol?
Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."
How were Synthetic Biologics' earnings last quarter?
Synthetic Biologics Inc (NYSEAMERICAN:SYN) posted its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.04) by $0.10. View Synthetic Biologics' Earnings History.
Where is Synthetic Biologics' stock going? Where will Synthetic Biologics' stock price be in 2017?
4 Wall Street analysts have issued twelve-month target prices for Synthetic Biologics' stock. Their predictions range from $5.00 to $6.00. On average, they anticipate Synthetic Biologics' share price to reach $5.50 in the next year. View Analyst Ratings for Synthetic Biologics.
Are investors shorting Synthetic Biologics?
Synthetic Biologics saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 7,176,264 shares, an increase of 3.9% from the October 13th total of 6,905,995 shares. Based on an average daily trading volume, of 880,277 shares, the short-interest ratio is presently 8.2 days. Currently, 6.3% of the shares of the company are sold short.
Who are some of Synthetic Biologics' key competitors?
Some companies that are related to Synthetic Biologics include Otonomy (OTIC), Recro Pharma (REPH), Shield Therapeutics PLC (STX), Cidara Therapeutics (CDTX), Agile Therapeutics (AGRX), Summit Therapeutics PLC (SMMT), Dimension Therapeutics (DMTX), XBiotech (XBIT), Intec Pharma (NTEC), Cellular Biomedicine Group (CBMG), DURECT Corporation (DRRX), Nivalis Therapeutics (ALPN), Cempra (MLNT), Adverum Biotechnologies (ADVM), OncoCyte Corp (OCX), Verastem (VSTM), Conatus Pharmaceuticals (CNAT) and ImmuPharma PLC (IMM).
Who are Synthetic Biologics' key executives?
Synthetic Biologics' management team includes the folowing people:
- Jeffrey Lucero Riley, President, Chief Executive Officer, Director (Age 46)
- Steven A. Shallcross, Chief Financial Officer, Treasurer, Secretary (Age 52)
- Joseph A. Sliman, Chief Medical Officer (Age 44)
- Jeffrey J. Kraws, Non-Executive Independent Chairman of the Board (Age 53)
- Scott L. Tarriff, Independent Director (Age 57)
- Jeffrey Alan Wolf J.D., Independent Director (Age 53)
How do I buy Synthetic Biologics stock?
Shares of Synthetic Biologics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Synthetic Biologics' stock price today?
One share of Synthetic Biologics stock can currently be purchased for approximately $0.68.
How big of a company is Synthetic Biologics?
Synthetic Biologics has a market capitalization of $86.44 million.
How can I contact Synthetic Biologics?
Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.
MarketBeat Community Rating for Synthetic Biologics (NYSEAMERICAN SYN)MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Synthetic Biologics (NYSEAMERICAN:SYN) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 2 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.50)|
|Consensus Price Target: ||$5.50|
Consensus Price Target History for Synthetic Biologics (NYSEAMERICAN:SYN)
Analysts' Ratings History for Synthetic Biologics (NYSEAMERICAN:SYN)
(Data available from 11/19/2015 forward)
|5/22/2017||William Blair||Reiterated Rating||Outperform||$5.00|
|1/14/2017||FBR & Co||Reiterated Rating||Overweight||$6.00|
|11/25/2016||Laurentian||Downgrade||Buy -> Speculative Buy|
|11/25/2016||Laurentian Bank of Canada||Downgrade||Buy -> Speculative Buy|
|8/31/2016||Griffin Securities||Set Price Target||Buy||$9.00 -> $5.80|
|8/25/2016||BTIG Research||Initiated Coverage||Buy||$5.00|
|2/5/2016||Royal Bank Of Canada||Reiterated Rating||Outperform||$8.00|
|1/4/2016||Telsey Advisory Group||Initiated Coverage||Outperform|
Earnings History and Estimates Chart for Synthetic Biologics (NYSEAMERICAN:SYN)
Earnings History by Quarter for Synthetic Biologics (NYSEAMERICAN SYN)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Synthetic Biologics (NYSEAMERICAN:SYN)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Synthetic Biologics (NYSEAMERICAN:SYN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Synthetic Biologics (NYSEAMERICAN SYN)
Insider Trades by Quarter for Synthetic Biologics (NYSEAMERICAN SYN)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/27/2015||Bartley Vaden Heath||Director||Buy||35,000||$0.28||$9,800.00|
|9/2/2015||Randal J Kirk||Major Shareholder||Buy||937,500||$3.20||$3,000,000.00|| |
|5/22/2014||Charles Evan Ballantyne||CFO||Buy||10,000||$1.35||$13,500.00|| |
|4/29/2014||Steve H Kanzer||Director||Sell||263,112||$2.90||$763,024.80|| |
|12/17/2013||Randal J Kirk||Major Shareholder||Buy||2,500,000||$1.00||$2,500,000.00|| |
|1/7/2013||Jeffrey Scott Riley||CEO||Buy||2,900||$0.17||$493.00|| |
|1/3/2013||Jeffrey Scott Riley||CEO||Buy||2,000||$1.71||$3,420.00|| |
|10/29/2012||Randal J Kirk||Major Shareholder||Buy||3,125,000||$1.60||$5,000,000.00|| |
Latest Headlines for Synthetic Biologics (NYSEAMERICAN SYN)
Synthetic Biologics (NYSEAMERICAN SYN) Chart for Sunday, November, 19, 2017